Skip to main content
SpringerLink
Log in

TFE/Translocation Morphology Renal Cell Carcinoma

  • Chapter
  • First Online:
Book cover Rare Kidney Tumors

  • 457 Accesses

Abstract

TFE/translocation renal cell carcinoma (tRCC) was formally recognized by the WHO in 2004 as a distinct, typically translocation-associated, RCC with characteristic morphology and immunohistochemical expression of TFE3 or TFEb. Cytogenetic translocations may include TFE3-ASPS, TFE3-PRCC, TFEb-alpha, or other variants; mechanisms for TFE upregulation may be heterogenous. TFE3 and TFEB are members of the MiTF/TFE family of basic helix-loop-helix-leucine zipper transcription factors [1–3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med. 2005;25:363–78.

    Article  Google Scholar 

  2. Argani P. The evolving story of renal translocation carcinoma. Am J Clin Pathol. 2006;126:332–4. Comment on: Am J Clin Pathol. 2006; 26:349–364

    Article  Google Scholar 

  3. Ramphal R, Pappo A, Zielenska M, Grant R, Ngan BY. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the Mit transcription factor family. Am J Clin Pathol. 2006;126:349–64.

    Article  CAS  Google Scholar 

  4. Geller JI, Argani P, Adeniran A, et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008;112:1607–16.

    Article  Google Scholar 

  5. Geller JI, Ehrlich PF, Cost NG, et al. Characterization of adolescent and pediatric renal cell carcinoma: a report from the Children's oncology group study AREN03B2. Cancer. 2015;121(14):2457–64.

    Article  Google Scholar 

  6. Ehrlich PF, Cost NG, Khanna G, et al. A description of the surgical experience in children, adolescents and young adults with renal cell carcinoma: a report from the Children's oncology group study AREN 03B2. BJU Int. 2012;110.(Supplement 2:18.

    Google Scholar 

  7. Zhong M, De Angelo P, Osborne L, et al. Translocation renal cell carcinomas in adults: a single-institution experience. Am J Surg Pathol. 2012;36(5):654–62.

    Article  Google Scholar 

  8. Kauffman E, Gupta G, Cecchi F, et al. Characterization of the Akt-mTOR pathway in TFE3-fusion renal cell cancers and implications for targeted therapy. Dent Abstr. 2012;448

    Google Scholar 

  9. Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010;116(22):5219–25.

    Article  CAS  Google Scholar 

  10. Malouf GG, Camparo P, Molinié V, et al. Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol. 2011;185(1):24–9. Epub 2010 Nov 12

    Article  CAS  Google Scholar 

  11. Camparo P, Vasiliu V, Molinie V, et al. Renal translocation carcinomas – Clinicopathologic, Immunohistochemical, and gene expression profiling, analysis of 31 cases with a review of the literature. Am J Surg Pathol. 2008;35:656–70.

    Article  Google Scholar 

  12. Meyer PN, Clark JI, Flanigan RC, et al. Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Am J Clin Pathol. 2007;128(1):70–9.

    Article  CAS  Google Scholar 

  13. Hung CC, Pan CC, Lin CC, et al. Xp11.2 translocation renal cell carcinoma: clinical experience of Taipei Veterans General Hospital. J Chin Med Assoc. 2011;74(11):500–4.

    Article  Google Scholar 

  14. Dal Cin P, Stas M, Sciot R, De Wever I, Van Damme B, Van den Berghe H. Translocation (X;1) reveals metastasis 31 years after renal cell carcinoma. Cancer Genet Cytogenet. 1998;101:58–61.

    Article  CAS  Google Scholar 

  15. Arnoux V, Long JA, Fiard G, et al. Xp11.2 translocation renal carcinoma in adults over 50 years of age: about four cases. Prog Urol. 2012;22(15):932–7.

    Article  CAS  Google Scholar 

  16. Geller J, Khoury J, and Dome J. Author’s Reply re: Letter to the Editor re: ‘Geller J and Dome J. Lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. October 1, 2004;101:1575–1583.’ Cancer 2005; 103(6):1318.

    Article  Google Scholar 

  17. Aoyagi T, Shinohara N, Kubota-Chikai K, et al. Long-term survival in a patient with node-positive adult-onset Xp11.2 translocation renal cell carcinoma. Urol Int. 2011;86(4):487–90.

    Article  Google Scholar 

  18. Hemesath TJ, Steingrimsson E, McGill G, et al. Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev. 1994;8:2770–80.

    Article  CAS  Google Scholar 

  19. Hodgkinson CA, Moore KJ, Nakayama A, et al. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell. 1993;74:395–404.

    Article  CAS  Google Scholar 

  20. Yasumoto K, Mahalingam H, Suzuki H, Yoshizawa M, Yokoyama K. Transcriptional activation of the melanocyte-specific genes by the human homolog of the mouse microphthalmia protein. J Biochem. 1995;118:874–81.

    Article  CAS  Google Scholar 

  21. Weterman AJ, van Groningen JJM, Jansen A, van Kessel AG. Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins. Oncogene. 2000;19:69–74.

    Article  CAS  Google Scholar 

  22. Kuiper RP, Schepens M, Thijssen J, et al. Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinoma due to promoter substitution. Hum Mol Genet. 2003;12:1661–9.

    Article  CAS  Google Scholar 

  23. Medendorp K, van Groningen JJM, Schepens M, et al. Molecular mechanisms underlying the MiT translocation subgroup of renal cell carcinomas. Cytogenet Genome Res. 2007;118:157–65.

    Article  CAS  Google Scholar 

  24. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007;67:919–29.

    Article  CAS  Google Scholar 

  25. McGill GG, Horstmann M, Widlund HR, et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell. 2002;109:707–18.

    Article  CAS  Google Scholar 

  26. Du J, Widlund HR, Hartsmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell. 2004;6:565–76.

    Article  CAS  Google Scholar 

  27. Busca R, Berra E, Gaggioli C, et al. Hypoxia-inducible factor 1α is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol. 2005;170:49–59.

    Article  CAS  Google Scholar 

  28. Nijman SMB, Hijmans EM, El Messaoudi S, van Dongen MMW, Sardet C, Bernards R. A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor-β. J Biol Chem. 2006;281:21582–7.

    Article  CAS  Google Scholar 

  29. Waterman MAJ, van Groningen JJM, Tertoolen L, van Kessel AG. Impairment of MAD2B-PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas. PNAS. 2001;98:13808–13.

    Article  Google Scholar 

  30. Mathur M, Samuels HH. Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas. Oncogene. 2007;26:277–83.

    Article  CAS  Google Scholar 

  31. Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001;20:48–57.

    Article  CAS  Google Scholar 

  32. Argani P, Zhong M, Reuter VE, et al. TFE3-fusion variant analysis defines specific clinicopathologic associations among Xp11 translocation cancers. Am J Surg Pathol. 2016;40:723–37.

    Article  Google Scholar 

  33. Rao Q, Liu B, Cheng L, et al. A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol. 2012;36:1327–38.

    Article  Google Scholar 

  34. Green WM, Yonescu R, Morsberger L, et al. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol. 2013;37:1150–63.

    Article  Google Scholar 

  35. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions. Am J Surg Pathol. 2003;27:750–61.

    Article  Google Scholar 

  36. Argani P, Lae M, Hutchinson B, et al. Renal carcinomas with the t (6;11)(p21;q12). Clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR and DNA PCR. Am J Surg Pathol. 2005;29:230–40.

    Article  Google Scholar 

  37. Malouf GG, Su X, Gao J, et al. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing patterns and frequent mutations of chromatin-remodeling genes. Clin Cancer Res. 2014;20:4129–40.

    Article  CAS  Google Scholar 

  38. Argani P. MiT family translocation renal cell carcinoma. Semin Diagn Pathol. 2015;32:103–13.

    Article  Google Scholar 

  39. Inamura K, Fujiwara M, Togashi Y, et al. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol. 2012;36:35–42.

    Article  Google Scholar 

  40. Argani P, Yonescu R, Morsberger L, et al. Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol. 2012;36:1516–26.

    Article  Google Scholar 

  41. Smith NE, Illei PB, Allaf M, et al. T(6;11) renal cell carcinoma (RCC) expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol. 2014;38:604–14.

    Article  Google Scholar 

  42. Argani P, Hicks J, De Marzo AM, et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol. 2010;34:1295–303.

    Article  Google Scholar 

  43. Martignoni G, Gobbo S, Camparo P, et al. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod Pathol. 2011;24:1313–9.

    Article  CAS  Google Scholar 

  44. Hong SB, Oh HB, Valera VA, Baba M, Schmidt LS, Linehan WM. Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. PLoS One. 2010;5(12):e15793.

    Article  Google Scholar 

  45. Macher-Goeppinger S, Roth W, Wagener N, et al. Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol. 2012;25:308–15.

    Article  CAS  Google Scholar 

  46. Cajaiba MM, Jennings LJ, Rohan SM, et al. ALK-rearranged renal cell carcinomas in children. Genes Chromosomes Cancer. 2016;55:442–51.

    Article  CAS  Google Scholar 

  47. Argani P, Reuter VE, Zhang L, et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol. 2016;40:1484–95.

    Article  Google Scholar 

  48. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer staging manual. 7th ed. New York: Springer-Verlag; 2010.

    Google Scholar 

  49. Crispen PL, Breau RH, Allmer C, et al. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol. 2011;59:18–23.

    Article  Google Scholar 

  50. Capitanio U, Becker F, Blute ML, et al. Lymph node dissection in renal cell carcinoma. Eur Urol. 2011;60:1212–20.

    Article  Google Scholar 

  51. Gorin MA, Ball MW, Pierorazio PM, et al. Partial nephrectomy for the treatment of translocation renal cell carcinoma. Clin Genitourin Cancer. 2015;13:e199–201.

    Article  Google Scholar 

  52. Xu L, Yang R, Gan W, et al. Xp11.2 translocation renal cell carcinomas in young adults. BMC Urol. 2015;15:57.

    Article  CAS  Google Scholar 

  53. Indolfi P, Bisogno G, Cecchetto G, et al. Local lymph node involvement in pediatric renal cell carcinoma: a report from the Italian TREP project. Pediatr Blood Cancer. 2008;51:475–8.

    Article  Google Scholar 

  54. Rialon KL, Gulack BC, Englum BR, et al. Factors impacting survival in children with renal cell carcinoma. J Pediatr Surg. 2015;50:1014–8.

    Article  Google Scholar 

  55. Karnes RJ, Blute ML. Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus. Nat Clin Pract Urol. 2008;5:329–39.

    Article  Google Scholar 

  56. Klatte T, Pantuck AJ, Riggs SB, et al. Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol. 2007;178:1189–95. discussion 1195

    Article  Google Scholar 

  57. Gayed BA, Youssef R, Darwish O, et al. Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15 year experience and lessons learned. BMC Urol. 2016;16:43.

    Article  Google Scholar 

  58. Thomas AZ, Adibi M, Borregales LD, et al. Surgical Management of Local Retroperitoneal Recurrence of renal cell carcinoma after radical nephrectomy. J Urol. 2015;194:316–22.

    Article  Google Scholar 

  59. Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16:2261–6.

    Article  CAS  Google Scholar 

  60. Wagner AJ, Goldberg JM, Dubois SG, et al. Tivantinib (ARQ 197), a selective inhibitor of mesenchymal-epithelial transition factor, in patients with microphthalmia transcription factor-associated tumors: Results of a multicenter phase 2 trial. Cancer. 2012 May 17. (epub ahead of print).

    Google Scholar 

  61. Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the juvenile RCC network. Ann Oncol. 2010;21(9):1834–8. Epub 2010 Feb 12

    Article  CAS  Google Scholar 

  62. Parikh J, Coleman T, Messias N, Brown J. Temsirolimus in the treatment of renal cell carcinoma associated with Xp11.2 translocation/TFE gene fusion proteins: a case report and review of literature. Rare Tumors. 2009;1(2):e53.

    PubMed  PubMed Central  Google Scholar 

  63. Massari F, Santoni M, Ciccarese C, et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev. 2015;41:114–21.

    Article  CAS  Google Scholar 

  64. Tannir NM, Jonasch E, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (the ESPN trial): a multicenter randomized phase 2 trial. J Clin Oncol. 2014;32:5s. suppl; abstr 4505

    Google Scholar 

  65. Liu YC, Chang PM, Liu CY, et al. Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11. 2 translocation renal cell carcinoma. Jpn J Clin Oncol. 2011;41(11):1277–81. Epub 2011 Sep 29

    Article  Google Scholar 

  66. Numakura K, Tsuchiya N, Yuasa T, et al. A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol. 2011;16(5):577–80. Epub 2010 Dec 15

    Article  Google Scholar 

  67. Hou MM, Hsieh JJ, Chang NJ, et al. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma. Clin Drug Investig. 2010;30(11):799–804.

    Article  CAS  Google Scholar 

  68. Pwint TP, Macaulay V, Roberts IS, Sullivan M, Protheroe A. An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib. Urol Oncol. 2011;29(6):821–4. Epub 2009 Dec 4

    Article  CAS  Google Scholar 

  69. Choueiri TK, Mosquera JM, Hirsch MS. A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. Clin Genitourin Cancer. 2009;7(3):E93–4.

    Article  Google Scholar 

  70. Chowdhury T, Prchard-Jones K, Sebire NJ, et al. Persistent complete response after single-agent Sunitinib treatment in a case of TFE translocation positive relapsed metastatic pediatric renal cell carcinoma. J Pediatr Hematol Oncol. 2013;35(1):e1–3.

    Article  Google Scholar 

  71. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9.

    Article  CAS  Google Scholar 

  72. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–7.

    Article  CAS  Google Scholar 

  73. McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving Nivolumab. J Clin Oncol. 2015;33(18):2013–20.

    Article  CAS  Google Scholar 

  74. Brunot A, Bernhard J-C, Yacoub M, et al. PDL-1 and PDL1 expressions in clear cell renal cell carcinoma (ccRCC) of metastatic patients with sunitinib first-line treatment. J Clin Oncol. 2015;33:15. suppl; abstr e14002

    Google Scholar 

  75. Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert Rev Anticancer Ther. 2015;15(9):981–93.

    Article  CAS  Google Scholar 

  76. Atkins MB, Choueiri TK, Hodi S, et al. Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): data from the KEYNOTE-029 phase 1 study. J Clin Oncol. 2015;33:3009. suppl; abstr 3009

    Article  Google Scholar 

  77. Cajaiba MM, Dyer LM, Geller JI, Jennings LJ, George D, Kirschmann D, Rohan SM, Cost NG, Khanna G, Mullen EA, Dome JS, Fernandez CV, Perlman EJ. The classification of pediatric and young adult renal cell carcinomas registered on the Children’s Oncology Group (COG) protocol AREN03B2 after focused genetic testing. Cancer. 2018; https://doi.org/10.1002/cncr.31578. [Epub ahead of print]

Download references

Author information

Authors and Affiliations

  1. Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA

    James I. Geller

  2. Division of Urology, Department of Surgery, Children’s Hospital Colorado, University of Colorado Cancer Center, Aurora, CO, USA

    Nicholas G. Cost

  3. Department of Pathology, University of Michigan, Ann Arbor, MI, USA

    Mariana M. Cajaiba

Authors
  1. James I. Geller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas G. Cost
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mariana M. Cajaiba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James I. Geller .

Editor information

Editors and Affiliations

  1. Department of Hematology and Oncology, Strasbourg University Hospital, Hopital Civil, Strasbourg, France

    Gabriel G. Malouf

  2. Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

    Nizar M. Tannir

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Geller, J.I., Cost, N.G., Cajaiba, M.M. (2019). TFE/Translocation Morphology Renal Cell Carcinoma. In: Malouf, G., Tannir, N. (eds) Rare Kidney Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-96989-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-96989-3_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-96988-6

  • Online ISBN: 978-3-319-96989-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation